Showing 2431-2440 of 3223 results for "".
- Unity Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in DMEhttps://modernod.com/news/unity-biotechnology-announces-topline-results-from-the-aspire-phase-2b-study-in-dme/2482712/Unity Biotechnology announced topline results from the phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. The study results include data from all patients through 24 weeks, and the majori
- Optos Unveils MonacoPro Ultra-Widefield and OCT Retinal Imaging Technologyhttps://modernod.com/news/optos-unveils-monacopro-ultra-widefield-and-oct-retinal-imaging-technology/2482688/Optos announced the launch of MonacoPro, the next generation ultra-widefield (UWF) SLO and spectral domain retinal imaging solution. Building on the legacy of Monaco, Optos said MonacoPro introduces features designed to elevate diagnostic precision and streamline workflow for eye care profes
- Nicox Announces New Data from the NCX 470 Mont Blanc Trial, Provides Development Updateshttps://modernod.com/news/nicox-announces-new-data-from-the-ncx-470-mont-blanc-trial-provides-development-updates/2482684/Nicox, an international ophthalmology company, shared new data on their intraocular pressure (IOP)-lowering medication NCX 470 at the 2025 American Glaucoma Society (AGS) Annual Meeting this past weekend. The French company also shared developmental updates from the 470 Mont Blanc phase 3 clinica
- Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolaminehttps://modernod.com/news/opus-genetics-announces-fda-fast-track-and-enrollment-updates-for-phentolamine-ophthalmic-solution/2482681/Opus Genetics announced completion of enrollment in the VEGA-3 phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia. Opus also announced that enrollment in the LYNX-2 pivotal phase 3 trial, evaluating phentolamine for the treat
- MyEyeDr. Partners with CoFi to Streamline Patient Paymentshttps://modernod.com/news/myeyedr-partners-with-cofi-to-streamline-patient-payments/2482673/MyEyeDr., which has 880 locations across the US, has teamed up with multi-party payment provider CoFi to simplify the payment process for patients requiring both optometry and ophthalmology services. This new partnership, now available in all 29 states where MyEyeDr. o
- Seonix Bio Launches SightScore, the First Clinical Polygenic Risk Score Test for Glaucoma in the UShttps://modernod.com/news/seonix-bio-launches-sightscore-the-first-clinical-polygenic-risk-score-test-for-glaucoma-in-the-us/2482672/Seonix Bio announced the US launch of SightScore, which the company descibes as the first commercially available clinical polygenic risk score testing service for primary open-angle glaucoma. Already available in Australia and New Zealand, SightScore utilizes
- FDA Clears New World Medical's VIA360 Surgical Systemhttps://modernod.com/news/fda-clears-new-world-medicals-via360-surgical-system/2482667/New World Medical has received 510(k) clearance from the FDA for its VIA360 Surgical System for the delivery of controlled amounts of viscoelastic fluid during ophthalmic surgeries. The VIA360, which is also indicated to cut trabecular meshwork tissue during trabecul
- Lumenis Launches OptiLIFT, Device to Address Lower Lid Laxity and Impaired Blinkinghttps://modernod.com/news/lumenis-launces-optilift-device-to-address-lower-lid-laxity-and-impaired-blinking/2482652/Lumenis announced the launch of OptiLIFT, a new device that uses Dynamic Muscle Stimulation technology (DMSt) to tone facial muscles to improve lower lid laxity and impaired blinking. OptiLIFT marks one of the first treatment options that eliminates the need for surgery. “Op
- Qlaris Bio Announces Positive Topline Data From Two Phase 2 Trials of QLS-111 for Glaucomahttps://modernod.com/news/qlaris-bio-announces-positive-topline-data-from-two-phase-2-trials-of-qls-111-for-glaucoma/2482647/Qlaris Bio announced positive topline results from two US phase 2 clinical trials investigating QLS-111 in patients with primary open angle glaucoma (POAG) and ocular hypertension (OHT). The trials (Osprey and Apteryx) successfully met all primary and secondary endpoints. Qlaris Bi
- Study Demonstrates Efficacy of AI in Enabling Home OCT Monitoringhttps://modernod.com/news/study-demonstrates-efficacy-of-ai-in-enabling-home-oct-monitoring/2482641/Notal Vision announced the publication of pivotal study results evaluating the performance of its artificial intelligence (AI) algorithm designed to estimate key biomarkers in wet age-